Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Apr;40(2):143-56.
doi: 10.1007/s10928-012-9294-9. Epub 2013 Jan 12.

Application of a mechanism-based disease systems model for osteoporosis to clinical data

Teun M Post  1 , Stephan Schmidt, Lambertus A Peletier, Rik de Greef, Thomas Kerbusch, Meindert Danhof
Affiliations
Randomized Controlled Trial

Application of a mechanism-based disease systems model for osteoporosis to clinical data

Teun M Post et al. J Pharmacokinet Pharmacodyn. 2013 Apr.

Abstract

A recently proposed mechanism-based disease systems model for osteoporosis (Schmidt et al., J Pharmacokinet Pharmacodyn 38:873-900, 2011) was applied to clinical data from post-menopausal women (n = 767) receiving various doses of the selective estrogen receptor modulator tibolone. Plasma bone-specific alkaline phosphatase activity and urinary N-telopeptide were used as biomarkers reflecting the activity of osteoblasts (bone forming cells) and osteoclasts (bone removing cells), respectively. These data were analyzed in conjunction with data on osteocalcin and on bone mineral density (BMD) (both lumbar spine and total hip), which reflect the activity of both cell types. While the dynamics of bone turnover markers changes rapidly, closely following changes in the activity of bone cells, changes in BMD are slower and have their own dynamics. Application of the mechanism-based disease systems model to the clinical data allowed for an adequate description of the data and yielded parameter estimates that are consistent with physiological values reported in the literature (Lemaire et al., J Theor Biol 229:293-309, 2004). The fitted model enabled characterization of (i) the critical time scales involved in disease progression, (ii) the dynamics of the system during onset and offset of the therapeutic intervention, and (iii) the distinction between responders and low-responders to tibolone treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Science. 2000 Sep 1;289(5484):1501-4 - PubMed
    1. Annu Rev Pharmacol Toxicol. 2007;47:357-400 - PubMed
    1. Climacteric. 2001 Jun;4(2):120-36 - PubMed
    1. J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78 - PubMed
    1. J Theor Biol. 2004 Aug 7;229(3):293-309 - PubMed

Publication types

MeSH terms

LinkOut - more resources

  NODES
admin 1
Association 1
twitter 2